2025
A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children
McGovern S, Johnson J, Luo D, Nguyen K, McAleer M, Paulino A, Grosshans D, Baxter P, Zaky W, Thall P, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: e13-e14. DOI: 10.1016/j.ijrobp.2024.11.049.Peer-Reviewed Original ResearchDose-volume constraintsSymptomatic brain necrosisRecurrent brain tumorsBrain tumorsBrain necrosisPrimary endpointDose constraintsProton therapyProspective studyRecurrent pediatric brain tumorsMedian overall survivalMedian prescription doseCourse of radiationResults Median ageTreated with radiationPediatric brain tumorsPrimary brain tumorProgression of diseaseBrain reirradiationDosimetric guidelinesDose escalationPrescription doseOverall survivalMedian intervalProspective trials
2024
Artificial intelligence in ophthalmology
Khossravi A, Chen Q, Adelman R. Artificial intelligence in ophthalmology. Current Opinion In Ophthalmology 2024, 36: 35-38. PMID: 39607311, DOI: 10.1097/icu.0000000000001111.Peer-Reviewed Original ResearchConceptsTreatment of diabetic retinopathyImprove accuracy of diagnosisProgression of diseasePersonalized treatment plansCorneal infectionVisual outcomeIntraocular pressureMacular degenerationDiabetic retinopathyAccuracy of diagnosisFollow-upTreatment planningOcular imagingPersonalization of medicinePredictive of progression of diseasePatient outcomesDiagnosisEnhance patient outcomesIncorporation of genomicsTreatmentHome monitoringOutcomesCornealGlaucomaEctasiaEvaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.Peer-Reviewed Original ResearchPrimary treatment failureAuto-HCTStable diseaseHodgkin lymphomaPartial responseCumulative incidence of non-relapse mortalityIncidence of non-relapse mortalityAssociated with inferior PFSEfficacy of auto-HCTAssociated with inferior OSAutologous hematopoietic cell transplantationEvaluation of prognostic factorsClassical Hodgkin lymphomaNon-relapse mortalityMulticenter retrospective cohortHigh-risk diseaseHematopoietic cell transplantationLong-term efficacyPatterns of failureUS medical centersProgression of diseaseInferior PFSMedian PFSInferior OSComplete responseRisk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy
Chakrani Z, Mellgard G, Saffran N, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 271-278. PMID: 38344754, DOI: 10.1097/coc.0000000000001087.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesReceptor-targeted therapyTreatment discontinuationSingle-institution retrospective review of patientsDiscontinued treatment due to toxicityTreatment discontinuation due to toxicityDiscontinued due to toxicityMultivariate analysisTreatment due to toxicityCastration-resistant prostate cancerSingle-institution retrospective reviewRetrospective review of patientsRisk of treatment discontinuationRisk factorsPatient-reported side effectsPatients discontinued treatmentTreatment-related toxicityEarly treatment discontinuationReview of patientsImprove survival outcomesDuration of treatmentLikelihood of treatment discontinuationProgression of diseaseTreatment toxicity
2023
Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART).
Chakrani Z, Mellgard G, Mccroskery S, Saffran N, Taylor N, Liaw B, Oh W, Tsao K, Patel V. Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART). Journal Of Clinical Oncology 2023, 41: 135-135. DOI: 10.1200/jco.2023.41.6_suppl.135.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesIncreased riskCastration-resistant prostate cancerSingle-institution retrospective reviewRisk factorsReceptor-targeted therapyMultivariate logistic regressionProgression of diseasePT reportingCancer ptsProstate cancerSurvival outcomesFisher's exactMedical historyClinical trialsOdds ratioSide effectsIncreased mortalityLogistic regressionHTNSignificant predictorsBivariate analysisDeathToxicityInterim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
Merryman R, Michaud L, Redd R, Mondello P, Park H, Spilberg G, Robertson M, Taranto E, Ahmed G, Chase M, Jeter E, Ahn I, Brown J, Crombie J, Davids M, Fisher D, Jacobsen E, Jacobson C, Kim A, LaCasce A, Ng S, Odejide O, Parry E, Salles G, Zelenetz A, Armand P, Schöder H, Jacene H. Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. HemaSphere 2023, 7: e826. PMID: 36713355, PMCID: PMC9875968, DOI: 10.1097/hs9.0000000000000826.Peer-Reviewed Original ResearchInterim positron emission tomographyProgression-free survivalPositron emission tomographyDeauville scoreFollicular lymphomaFrontline chemoimmunotherapyMultivariable analysisSignificant predictorsResponse-adapted treatment strategiesTreatment positron emission tomographyInferior progression-free survivalEmission tomographyMaximum standardized uptake valueHigh-grade follicular lymphomaHigh-risk patientsSubset of patientsStandardized uptake valueProgression of diseaseMost patientsIndependent predictorsExcellent outcomesEarly progressionTreatment strategiesEarly predictorSeparate cohort
2022
Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)
Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404). Journal Of Clinical Oncology 2022, 40: 4240-4249. PMID: 35867947, PMCID: PMC9916043, DOI: 10.1200/jco.22.00229.Peer-Reviewed Original ResearchConceptsSalivary gland cancerPrimary end pointProgression-free survivalAndrogen receptorStable diseaseEnd pointOverall survivalPartial responseGland cancerTumor regressionPartial response/stable diseaseBest overall response rateMedian progression-free survivalResponse/stable diseaseHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Common adverse eventsMedian overall survivalPhase II studySecondary end pointsPhase II trialFree testosterone levelsGrowth factor receptor 2Overall response rateProgression of diseasePredictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.Peer-Reviewed Original ResearchConceptsMarginal zone lymphomaRefractory marginal zone lymphomaMulticenter cohort studyPrimary refractory diseaseOverall response rateStable diseaseCohort studyComplex cytogeneticsRefractory diseaseFirst-line therapyHigh-risk subsetType of therapyProgression of diseaseInferior OSInferior PFSMedian PFSPartial responsePredictive factorsExperimental therapiesStudy populationEligibility criteriaClinical practicePatientsResponse rateIbrutinibSafety and efficacy of an outpatient 12-step desensitization protocol for antineoplastic agents
Eroglu I, Filippova OT, Kirrane M, Orpen M, Almonte V, Thomas R, Lee-Teh M, Tizon R, Sklarin N, O’Cearbhaill R. Safety and efficacy of an outpatient 12-step desensitization protocol for antineoplastic agents. International Journal Of Gynecological Cancer 2022, 32: 1056-1062. PMID: 35675969, PMCID: PMC9924431, DOI: 10.1136/ijgc-2022-003466.Peer-Reviewed Original ResearchDesensitization protocolHypersensitivity reactionsInfusion timeAntineoplastic agentsCycles of therapyExtended infusion timeMedian infusion timePrior hypersensitivity reactionLeukotriene receptor antagonistsProgression of diseaseEligible patientsSuccessful desensitizationMedian ageRetrospective reviewColorectal cancerInpatient admissionsAntineoplastic therapyReceptor antagonistPatient outcomesLiposomal doxorubicinOvarian cancerMedian numberPatientsSpecific agentsDesensitization
2021
Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma
Witzig T, Sokol L, Kim W, de la Cruz Vicente F, Caballero D, Advani R, de Oña R, Niebla A, Terol M, Eva D, Bendris N, Ahsan J, Leoni M, Foss F. Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood 2021, 138: 621. DOI: 10.1182/blood-2021-147279.Peer-Reviewed Original ResearchAngioimmunoblastic T-cell lymphomaProgression-free survivalOverall response rateT-cell lymphomaOverall survivalPeripheral T-cell lymphomaT-cell non-Hodgkin lymphomaOpen-label trialPhase 2 studyNegative prognostic factorDuration of responsePotential predictive biomarkersNon-Hodgkin lymphomaT-cell homingProgression of diseasePTCL patientsRefractory PTCLUnacceptable toxicityAdult patientsPrognostic factorsPredictive biomarkersLugano classificationCXCL12 expressionReceptor CXCR4New therapiesVaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
Doyle HA, Gee RJ, Masters TD, Gee CR, Booth CJ, Peterson-Roth E, Koski RA, Helfand SC, Price L, Bascombe D, Jackson D, Ho R, Post GR, Mamula MJ. Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Translational Oncology 2021, 14: 101205. PMID: 34419682, PMCID: PMC8379704, DOI: 10.1016/j.tranon.2021.101205.Peer-Reviewed Original ResearchEpidermal growth factor receptorAnti-tumor immunityMonoclonal antibody therapyEGFR/HER2Antibody therapyPhase I/II open label studyCanine cancersHuman epidermal growth factor receptorImmune modifying therapiesOpen-label studyCD8 T cellsHuman cancersStandard cancer therapiesProgression of diseaseInhibited tumor growthSpontaneous canine cancersGrowth factor receptorMonoclonal therapyCheckpoint inhibitorsModifying therapiesIgG depositionObjective responseVaccine therapyMetastatic sitesAntigen responseRisk of chronic arthralgia and impact of pain on daily activities in a cohort of patients with chikungunya virus infection from Brazil
Silva M, Kikuti M, Anjos R, Portilho M, Santos V, Gonçalves T, Tauro L, Moreira P, Jacob-Nascimento L, Santana P, Campos G, Siqueira A, Kitron U, Reis M, Ribeiro G. Risk of chronic arthralgia and impact of pain on daily activities in a cohort of patients with chikungunya virus infection from Brazil. International Journal Of Infectious Diseases 2021, 105: 608-616. PMID: 33684559, DOI: 10.1016/j.ijid.2021.03.003.Peer-Reviewed Original ResearchConceptsChronic arthralgiaChikungunya virus infectionRisk factorsVirus infectionDaily activitiesAcute febrile illnessIndependent risk factorPersistence of painCohort of patientsImpact of painProgression of diseaseTranscriptase-polymerase chain reactionPersistent arthralgiaFebrile illnessSubstantial disabilityViral loadFemale sexPolymerase chain reactionIgM enzymeArthralgiaSurveillance studyChikungunya virusDengue virusPatientsImmunosorbent assay
2019
Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.
Ho A, Foster N, Zoroufy A, Worden F, Price K, Adkins D, Bowles D, Kang H, Burtness B, Sherman E, Morton R, Katabi N, Munster P, Schwartz G. Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers. Journal Of Clinical Oncology 2019, 37: 6020-6020. DOI: 10.1200/jco.2019.37.15_suppl.6020.Peer-Reviewed Original ResearchProgression-free survivalSalivary gland cancerProgression of diseaseAndrogen receptorOverall survivalStable diseaseMedian progression-free survivalGood responsePhase II studyFirst prospective trialPhase II trialEligible patientsPrior therapyRECIST v1.1Salivary cancerUnconfirmed PRHormonal therapyII trialPrimary endpointSecondary endpointsII studyProspective trialGland cancerClinical activityConfirmatory scanWhat are the most promising new agents in myelodysplastic syndromes?
Chandhok NS, Boddu PC, Gore SD, Prebet T. What are the most promising new agents in myelodysplastic syndromes? Current Opinion In Hematology 2019, 26: 77-87. PMID: 30632987, DOI: 10.1097/moh.0000000000000483.BooksConceptsMyelodysplastic syndromePromising new agentNew agentsAllogeneic hematopoietic stem cell transplantationManagement of MDSHigh-risk myelodysplastic syndromeHematopoietic stem cell transplantationRisk myelodysplastic syndromesLong-term remissionStem cell transplantationHigh-risk groupLow-risk groupGoal of therapyAcute myeloid leukemiaProgression of diseaseBone marrow failure syndromesGroup of disordersQuality of lifeMarrow failure syndromesTransfusion dependenceTherapeutic optionsTreatment optionsBcl-2 inhibitorsDisease prognosticationMyeloid leukemia
2018
Disparities in length of goals of care conversations between oncologists and patients with advanced cancer.
Smith C, Pintova S, Adelson K, Gonsky J, Egorova N, Bickell N. Disparities in length of goals of care conversations between oncologists and patients with advanced cancer. Journal Of Clinical Oncology 2018, 36: 19-19. DOI: 10.1200/jco.2018.36.34_suppl.19.Peer-Reviewed Original ResearchNon-minority patientsProgression of diseaseMinority patientsAdvanced cancerCancer patientsHigh-quality cancer careAdvanced cancer patientsGoals of careMinority cancer patientsNon-Hispanic blacksNon-Hispanic whitesPaucity of dataGOC conversationsGOC discussionsCancer carePoor survivalCare conversationsPatientsRural hospitalsSubstandard treatmentCommunication skills trainingOncologistsCancer treatmentRisk adjustmentMixed-effects modelsClinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2018, 13: 831-839. PMID: 29578107, PMCID: PMC6485248, DOI: 10.1016/j.jtho.2018.03.008.Peer-Reviewed Original ResearchConceptsPD-1 axis inhibitorsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerInhibitor therapyLocal therapyLymph nodesLung cancerSurvival rateSolid Tumors v1.1Response Evaluation CriteriaSite of diseaseProgression of diseaseProgressive diseaseClinical patternLN metastasisSuch patientsClinical featuresMedian timeRadiographic featuresTumor regressionProlonged benefitPatientsTherapyResponse criteriaSafety and feasibility of immuno-cryotherapy.
Raja J, Ghodadra A, Gettinger S, Kluger H, Sznol M, Schalper K, "Kevin" Kim H. Safety and feasibility of immuno-cryotherapy. Journal Of Clinical Oncology 2018, 36: 34-34. DOI: 10.1200/jco.2018.36.5_suppl.34.Peer-Reviewed Original ResearchAdverse eventsImage-guided cryotherapyGrade 3Metastatic non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitor resistanceImmune checkpoint inhibitor therapyAdverse Events criteriaCheckpoint inhibitor resistanceCheckpoint inhibitor therapyCTLA-4 blockadeDisease control rateHigher adverse eventsImmune checkpoint inhibitionPrimary end pointImmune checkpoint therapyCell lung cancerTypes of malignanciesCases of diarrheaProgression of diseaseSystemic immunotherapyMetastatic NSCLCPeriprocedural periodSecondary endpointsSite hematoma
2017
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors
Raj N, Klimstra D, Horvat N, Zhang L, Chou J, Capanu M, Basturk O, Gian R, Allen P, Reidy-Lagunes D. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas 2017, 46: 758-763. PMID: 28609363, PMCID: PMC5509357, DOI: 10.1097/mpa.0000000000000842.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic Agents, AlkylatingBiomarkers, TumorCell DifferentiationChildDacarbazineDatabases, FactualDisease ProgressionDNA MethylationDNA Modification MethylasesDNA Repair EnzymesDrug Resistance, NeoplasmFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingNeuroendocrine TumorsPancreatic NeoplasmsPharmacogeneticsPromoter Regions, GeneticSequence Analysis, DNATemozolomideTime FactorsTreatment OutcomeTumor Suppressor ProteinsYoung AdultConceptsPancreatic neuroendocrine tumorsProgression of diseaseWD-panNETsStable diseasePartial responseNeuroendocrine tumorsAlkylating agentsAlkylating agent therapyResponse Evaluation CriteriaResistance to alkylating agentsMGMT deficiencyAgent therapyEvaluation CriteriaSolid tumorsMGMTTumorGlioblastoma multiformePanNETsPatientsDiseaseDecreased activityDNA methyltransferasesAgentsRECISTStatusMulti-modality surgical treatment for an increasingly common patient with morbid obesity and papillary thyroid carcinoma
Ichter ZA, Parthasarathy M, Morton JM. Multi-modality surgical treatment for an increasingly common patient with morbid obesity and papillary thyroid carcinoma. Journal Of Surgical Case Reports 2017, 2017: rjw200. PMID: 28603603, PMCID: PMC5460003, DOI: 10.1093/jscr/rjw200.Peer-Reviewed Original ResearchGastric bypass surgeryCoronary artery diseasePapillary thyroid cancerProgression of diseasePapillary thyroid carcinomaMajority of casesMorbid obesityBypass surgeryMetastatic diseaseSurgical resectionArtery diseaseSurgical treatmentPostoperative carePatient presentsThyroid cancerCommon patientsRadiation therapyThyroid carcinomaTherapeutic radiationNew diagnosisHealth disordersPhysicians faceDiseaseObesityPatientsIntroduction to Bayesian variable selection methods in high-dimensional omics data analysis
Dong X, Xu S, Tao R, Wang T. Introduction to Bayesian variable selection methods in high-dimensional omics data analysis. Chinese Journal Of Epidemiology 2017, 38: 679-683. PMID: 28651411, DOI: 10.3760/cma.j.issn.0254-6450.2017.05.025.Peer-Reviewed Original ResearchConceptsBayesian variable selection methodOmics dataBayesian variable selectionAnalysis of high-dimensional dataDevelopment of genome sequencing technologyVariable selection methodsHigh-dimensional omics data analysisCase nGenome sequencing technologiesOmics data analysisVariable selectionVariable PHigh-dimensional dataSequencing technologiesStatistical challengesMeasure thousandsOmicsProgression of diseaseBioinformatics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply